AstraZeneca H1 and Q2 2025 Financial Results

AstraZeneca reported strong financial performance for the first half and second quarter of 2025, with total revenue increasing by 11% to $28,045 million. The growth was driven by double-digit increases in Oncology and BioPharmaceuticals, with significant contributions from key products like Tagrisso, Imfinzi, and Farxiga. The company also highlighted 12 positive Phase III trial readouts and 19 regulatory approvals in major regions. AstraZeneca announced a $50 billion investment in US manufacturing and R&D, including a new facility in Virginia. Core EPS increased by 17% to $4.66, and the interim dividend was raised by 3%. The company reiterated its guidance for high single-digit revenue growth and low double-digit Core EPS growth for FY 2025.